Compare Godaddy Inc (GDDY) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Godaddy Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Godaddy Inc trades at $102.04 (market cap $13.07B), while Vertex Pharmaceuticals Incorporated trades at $503.25 (market cap $127.55B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 9.8× Godaddy Inc's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Godaddy Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Godaddy Inc for 65 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| GDDY | VRTX | |
|---|---|---|
Market Cap | $13.07B | $127.55B |
Volume | 1,831,274 | 1,487,944 |
Sector | Technology | Health |
52-Week High | $135.18 | $557.96 |
52-Week Low | $75.07 | $407.37 |
Typical Hold Time | 65 Days | 120 Days |
Enterprise Value | $15.75B | $121.68B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GoDaddy (GDDY) trades at $97.21, down 0.99% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company maintains strong fundamentals with consistent earnings beats, posting $4.95B revenue and $875M net income in 2025. Valuation metrics appear reasonable with P/E of 14.44 and P/S of 2.58. However, the stock faces significant headwinds from multiple securities class action lawsuits alleging misrepresentation of domain contract terms, creating investor uncertainty despite positive financial performance.
The outlook remains mixed with strong operational performance offset by legal risks. Analyst consensus leans bullish with 57.9% buy ratings and $96.20 price target, but the numerous securities lawsuits represent material downside risk. Investors should weigh the company's solid profitability and cash flow generation against potential legal liabilities and reputational damage from the ongoing litigation.
Vertex Pharmaceuticals (VRTX) trades at $505.64, up 0.63% on the day, with a bearish technical signal despite a neutral oscillator reading. The company reported strong 2025 revenue of $12.00B and net income of $3.95B, with a net margin of 35%. Recent positive Phase 2b data for its kidney disease drug inaxaplin highlights pipeline expansion beyond cystic fibrosis dominance. Analyst consensus is strongly bullish with an 83.9% buy rating and a $573.50 price target, implying 13.4% upside.
The outlook for VRTX is positive, driven by its profitable core business and promising pipeline, but faces risks from clinical trial outcomes and competitive pressures. The stock's current valuation at a P/E of 29.45 is reasonable given its growth prospects, though investors should monitor execution on new drug approvals and market adoption.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Godaddy Inc
GoDaddy is a provider of domain registration and aftermarket services, website hosting, security, design, and business productivity tools, commerce solutions, and domain registry services. The company primarily targets micro- to small businesses, website design professionals, registrar peers, and domain investors. Since acquiring payment processing platform Poynt in 2021, the company has expanded into omnicommerce solutions, including offering an online payment gateway and offline point-of-sale devices.
Read more on GDDY →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
